Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study Newsfile - Thu Apr 11, 6:16AM CDT

Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences Newsfile - Fri Apr 5, 6:16AM CDT

Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor conferences.Kiora...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting Newsfile - Thu Mar 28, 6:00AM CDT

Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Newsfile - Mon Mar 25, 6:16AM CDT

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the...

KPRX : 0.4700 (-2.08%)
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye Newsfile - Fri Mar 8, 6:02AM CST

Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million Newsfile - Wed Jan 31, 5:48PM CST

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties Newsfile - Wed Jan 31, 4:28PM CST

Kiora to webcast investor conference call at 5:30 pm today; details belowEncinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ:...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa Newsfile - Thu Nov 9, 2023

Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing...

KPRX : 0.4700 (-2.08%)
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa Newsfile - Sat Nov 4, 2023

Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional visionFunctional MRI demonstrates...

KPRX : 0.4700 (-2.08%)
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference Newsfile - Mon Oct 16, 2023

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor...

KPRX : 0.4700 (-2.08%)

Barchart Exclusives

2 Shipping Dividend Stocks to Buy at a Discount Barchart - Sat Apr 27, 2:00PM CDT
With shipping disruptions in the Red Sea and high freight rates acting as tailwinds for the sector, these two dividend-paying shipping stocks trading at attractive valuations could be smart investments now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot